Xenetic Biosciences Reports Q3 2025 Financial Results

Xenetic Biosciences, Inc., a biopharmaceutical company advancing immuno-oncology technologies, has announced its financial results for the third quarter of 2025. The company reported a net loss of approximately $0.5 million. Research and development expenses saw a significant increase, rising by 105.6% to $0.8 million, attributed to enhanced manufacturing and pre-clinical efforts.

General and administrative expenses increased by 9.3% to $0.8 million, mainly due to legal costs. Revenue rose by 67.2% to $1.0 million, largely driven by increased royalties from a sublicense agreement with Takeda Pharmaceuticals. The company ended the quarter with $4.1 million in cash and secured $3.9 million from a recent offering.

Xenetic is advancing its DNase technology towards Phase 1 clinical trials, focusing on pancreatic carcinoma treatment. The company has also entered into a Clinical Trial Services Agreement with PeriNess for exploratory studies in Israel.